our progress
|
|
building momentum
Since our founding, we have funded over 180 research projects laser-focused on bringing life-saving therapies and cures to the EB community. Our work has transformed the clinical trial landscape from just 2 clinical trials in EB to over 50 today, an over 25x increase.
Over the last decade, EBRP has made remarkable strides, including helping to accelerate the first three FDA-approved EB treatments in the past two years alone. Two of these treatments were directly funded by EBRP under our Venture Philanthropy model.
Active studies showing
promise and progress.
promise and progress.
Pivotal studies to confirm
safety and effectiveness.
safety and effectiveness.
Under FDA review
for evaluation.
for evaluation.
Approved therapies
available for patients.
available for patients.
funded Research highlights
|
"Modeling and Targeting RDEB with Human Skin Organoids-on-Chip"
"Developing Ex-vivo and In-vivo Base and Prime Editing Strategies to Treat Recessive Dystrophic Epidermolysis Bullosa"
|
"Utilizing SRI-41315 Alone and in Combination with Gentamicin to Promote Readthrough in Patients with RDEB and JEB" "Nonsense readthrough using gentamicin or ELX-02 in combination with potentiator compounds for the treatment of Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa" |
"Validating New Anti-Cancer Targets for Dystrophic Epidermolysis Bullosa"
"Phase 2 Trial of a Neurokinin-1 Receptor Antagonist for the Treatment of Chronic Itch in Epidermolysis Bullosa Patients"
|
MAKE A DONATION
Thanks to EBRP's pioneering Venture Philanthropy model, every donation has the potential to grow to multiples of its original value.
Donate today to fund the science that will find the cure.
Donate today to fund the science that will find the cure.
|
|
